Latest Stock Buy or Sell? Make More Informed Decisions!

Markets tend to be fairly placid or weak when it comes to what they want and need. For the last few years, it's all been rates. As a long-term investor of quality companies, he'd much rather have a strong economy with strong earnings, and let rates take care of themselves.

Good companies can navigate a variety of different scenarios. Historically speaking, rates, even where they are today, are lower than average. So the idea that the market's worried about whether a rate cut will come in March or June is completely incidental to him. He's looking for good companies, strong earnings, good revenue growth, moats to their business. All these things will lead him to good places in the long term.

Technology gets most of the headlines, and rightfully so. Another good earnings season by most companies, led by META, which has reinvented itself from the abyss and its fundamental numbers have proven that. We also got really good reports from AMZN. Though the market didn't react particularly positively, GOOG's report was solid, it's a great company.

Market weight on the Magnificent 7 is about 30%. At his firm, he has only about 15% exposure. He likes it very much, but doesn't want to overly concentrate and create undue risk for clients. The other 493 companies that aren't in the Magnificent 7 also have great value. Trading at 16-17x earnings, fabulous choice there from an industry, sector, and company standpoint.

Likes industrials. Still likes financials, though they're a quarter or two away from responding well. Lots of opportunity to look at.

Solid industrial. Likes its fundamentals and projected earnings, but the chart shows how well it's done. When things rise in price, they tend to drop in value. Normally trades at slight discount to market, now at a premium. Going to have to do really well to live up to its valuation. He owns RTX.

Within the sector, there's really good fundamental growth and stocks are responding. Because they're somewhat cyclical, they tend to be more trading vehicles within a long-term portfolio, rather than growth stocks that you might own for multiple cycles and multiple years. You have to be on top of them and watch them. Make sure they don't grow themselves to a point where they're exposed from a valuation standpoint.

Long run of underperformance. Consistently missed on objectives and timing. Recently, has piggybacked on strength in the market. Might do a 180 turn and get their mojo back, but lots of risk associated with that premise. He'd go with QCOM or AVGO.

Has done well on fundamentals, not excessively expensive. More concentrated in the AI space.

Has done well on fundamentals, not excessively expensive. Less of a pure AI play, so not as sensitive to moves in that area. Broader diversification. Trades at 60-70% of the valuation of AVGO.

Appreciates what it's done. Trades north of 50x current earnings, expected growth rate is pretty exciting. Ask yourself: is it worth paying up, when peers are trading around 15x? He'd look at AMGN.

Down a bit on earnings report this morning, but overlook that, short-term reaction. Phase 1 weight-loss drug primed to compete with LLY's, though not yet being promoted as its next blockbuster. Much more modest multiple than LLY.

Not inexpensive. Fundamentals show it's an absolute cash machine, over $116B in cash from operations. What they do with that cash will impact its future. Great to own because of firepower of its size, scale, and business model.

Great company, Covid saviour. Ran up on that, now falling off. Back to more normalized levels. Not his first choice. He owns MRK.

Better pipeline than PFE. Very strong oncology drug, proving effective in cocktail form against different cancers. This one drug represents over 40% of revenues. Patent on this one runs off around 2027-28, but pipeline is robust.

Happy with it. High-bar for last earnings report, so market reaction was tepid. Good, solid earnings. Trades 20-22x forward earnings, very inexpensive when earnings will grow in mid-high teens for as far as the eye can see. Solid, will keep capital safe when markets go sideways or south.

Expensive, and he's never understood why. Trades around 25-30x earnings. Most competitors trade 10-12 points lower. Pass.

Reasonable multiple, mid-high teens. Good growth rate, highly predictable. Has a GLP-1 candidate, good results in Phase 1 testing. 17% of revenue goes back into R&D.